An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab and Cemiplimab in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, run by Rakuten Medical, Inc., active and no longer recruiting.
Overview
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04305795 by Rakuten Medical, Inc., with 23 participants enrolled, started 2020-12-21 and due to reach its primary completion in 2026-06. Interventions recorded: 200 mg Pembrolizumab, 350 mg Cemiplimab and ASP-1929 PIT.
Similar pages
not linked directly; found by shared links- TrialASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Shares Rakuten Medical, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Study of IDP-001 in Advanced or Metastatic Solid Tumors
Shares Cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma and the tag pipeline.
- TrialSafety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialIxovex-1 Single Agent and Combination Therapy
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Shares Cemiplimab and the tag pipeline.
- TrialA Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.
- TrialA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Head and neck squamous cell carcinoma, Pembrolizumab and the tag pipeline.